Anne Li August 12th, 2017 email@example.com
Cancer immunotherapies that block two different checkpoints on T cells launch immune attacks on cancer by expanding distinct types of T cell that infiltrate tumors. Researchers analyzed infiltrating immune cells from mouse tumor models and human melanomas treated with either anti-CTLA-4 or anti PD-1 checkpoint inhibitors. Using mass cytometry, they analyzed 33 surface markers and 10 intracellular markers to characterize infiltrating cells.
See original article at: https://www.sciencedaily.com/releases/2017/08/170810124952.htm